Development & Aid, Europe, Headlines, Health

HEALTH\AIDS: Global Meet Seeks Elusive Solution To AIDS Pandemic

Dipankar De Sarkar

GENEVA, Jun 29 1998 (IPS) - Experts from all over the world have gathered in Geneva to bring themselves up to date with the latest advances in the war against AIDS.

The theme of the conference is ‘Bridging the Gap’, a reference to the divide between developing and developed countries; the rich and the poor within countries; men and women; doctors and social workers; and adults and youth.

“It is a political problem, something that cannot be managed by doctors only,” Guy-Olivier Segond, who is responsible for health and social affairs for the Canton of Geneva, told the inaugural gathering.

“What are drug producers doing about it? Are we in the North not guilty of non-assistance to persons in danger? What is the role of private research?” he asked.

With the gap between affluent and poor nations widening with every medical innovation, those questions are among many that the gathered delegates will seek to answer over the coming days.

Close to 13,000 delegates — scientists, doctors and community workers, and 1,000 journalists — are participating in the six day 12th World AIDS Conference, which opened here Sunday.

About 30 million people live with HIV/AIDS all over the world, 90 percent of them in developing countries. And within the developing regions, the most people affected with the disease are in sub- Saharan Africa, the poorest region of the world.

At the same time, medical innovations in the affluent countries of the West mean that AIDS is becoming a more manageable disease — though far from curable. Long-term therapies with anti- retroviral drugs such as AZT can minimise the side effects of AIDS.

However, because of their prohibitive costs, these drugs are beyond the reach of most HIV positive people in developing countries. AZT therapies cost upward of 10,000 dollars a year and the course has to be maintained for the entirety of an AIDS patient’s life.

In many developing countries the amount of 10,000 dollars represents the entire budget of a hospital for a whole year, according to experts here. In some poor countries, the health budget per person per year is a mere 10 dollars.

In India, where the number of AIDS patients is predicted to outstrip that of all other countries in the near future, the proportion spent on health in the national budget has been steadily slipping year by year.

“The number of Indians with HIV/AIDS is five million at present and is expected to reach 10 million by the end of the century. But an average Indian just cannot support this kind of long-term therapy with AZT,” said Dr Surya Rao Kutikuppala, a senior physician from the southern Indian city of Vishakhapattanam.

He claimed that the international community has, from the very start of the AIDS crisis, left the developing world out when sharing the benefits of advances in medical sciences. “At least they can give us an assurance that will do something,” Rao said.

Many community workers and members of the medical establishment in developing countries blame the developed world for not trying hard enough to make expensive drugs available to people in poor countries and for not investing enough money into a cheap AID S vaccine.

In many respects, the AIDS vaccine — or the lack of it — has come to symbolise all that is considered unfair in efforts to combat the spread of the disease.

The search for a vaccine is one of the major areas of discussion at the conference, which comes just a week after the first ever tests with an AIDS vaccine called RGP 120. RGP 120 is to be tested in multiple sites in the United States by a California dru gs company called Daxgen, with the possibility of later large- scale tests in Thailand.

“We are years into the AIDS crisis and the first vaccine trials were held only last week, with the next batch of tests happening not before the year 2000,” said Dr Seth Berkley of the International AIDS Vaccine Initiative (IAVI), a nonprofit organisati on committed to developing safe, effective, accessible and preventive AIDS vaccines.

IAVI Sunday unveiled a new package for developing such a vaccine with a 1.5 million dollar donation from Bill Gates, the world’s richest individual and founder of software firm Microsoft.

“The world is not on track to meet the goal of a safe and effective AIDS vaccine in the next decade,” said Margaret Johnston, Vice president for Scientific Affairs at IAVI. “this programme will not only put us back on track, it will put us on a fast t rack.”

Nevertheless, disputes rage within the so-called AIDS community on who is to blame for the spread of the AIDS pandemic in developing countries: the developing countries themselves or the developed nations.

It is a hotly debated issue that in many ways is at the heart of the Geneva conference. Many developing countries think affluent Western nations only stand and look while their pharmaceutical multinationals reap profits from expensive medication while re fusing to help those in poor countries.

“There is no way you should make money when you have sick people,” said Major Rubaramira Ruranga of Uganda, who himself is HIV-positive and is a delegate to the conference.

Equally, many other experts hold that the developing countries themselves should bear responsibility for caring for the AIDS populations and should spend more on health.

“If Uganda and Thailand can bring down the rate of new infections, why can’t other countries?” said Peter Piot of the Joint United Nations Programme on AIDS (UNAIDS). “Resources must come from the countries in the first instance, but also from the int ernational community.”

And he defended UNAIDS from the charge of not trying enough for developing countries, as the organisation only has a budget of 60 million dollars, small in U.N.; terms and miniscule given the scale of the problem.

Ironically the gap between North and South was immediately visible in the conference auditorium itself. Although 90 percent of AIDS patients worldwide are in developing countries, only 70 percent of this week’s participants are from developed countries, according to conference chair Bernard Hirschel.

“Access to such conferences is not easy for participants from developing countries,” said one delegate, pointing out that the registration fee of about 1,000 Swiss francs was prohibitive for many.

 
Republish | | Print |

Related Tags